CuATSM结构式
|
常用名 | CuATSM | 英文名 | CuATSM |
---|---|---|---|---|
CAS号 | 68341-09-3 | 分子量 | 321.91 | |
密度 | N/A | 沸点 | N/A | |
分子式 | C8H14CuN6S2 | 熔点 | N/A | |
MSDS | 美版 | 闪点 | N/A |
CuATSM用途CuATSM是一种高效的自由基捕获抗氧化剂(RTA)和(磷酸)脂质过氧化抑制剂,因此具有抑制铁下垂的能力。 |
中文名 | [[2,2′-(1,2-二甲基-1,2-乙二亚甲基)双[N-甲基肼甲硫代酰胺基]]]铜 |
---|---|
英文名 | 0YDK1H9L3A |
英文别名 | 更多 |
描述 | CuATSM是一种高效的自由基捕获抗氧化剂(RTA)和(磷酸)脂质过氧化抑制剂,因此具有抑制铁下垂的能力。 |
---|---|
相关类别 | |
参考文献 |
分子式 | C8H14CuN6S2 |
---|---|
分子量 | 321.91 |
精确质量 | 321.001740 |
外观性状 | powder |
储存条件 | 2-8°C |
水溶解性 | DMSO: soluble10mg/mL, clear |
危险品运输编码 | NONH for all modes of transport |
---|---|
WGK德国 | 3 |
Zn II(atsm) is protective in amyotrophic lateral sclerosis model mice via a copper delivery mechanism.
Neurobiol. Dis. 81 , 20-4, (2015) Mutations in the metalloprotein Cu,Zn-superoxide dismutase (SOD1) cause approximately 20% of familial cases of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease for which effectiv... |
|
Oral treatment with Cu(II)(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis.
J. Neurosci. 34(23) , 8021-31, (2014) Mutations in the metallo-protein Cu/Zn-superoxide dismutase (SOD1) cause amyotrophic lateral sclerosis (ALS) in humans and an expression level-dependent phenotype in transgenic rodents. We show that o... |
|
Therapeutic effects of CuII(atsm) in the SOD1-G37R mouse model of amyotrophic lateral sclerosis.
Amyotroph. Lateral Scler. Frontotemporal Degener. 14(7-8) , 586-90, (2013) Our objective was to assess the copper(II) complex of diacetylbis(4-methylthiosemicarbazone) [Cu(II)(atsm)] for its preclinical potential as a novel therapeutic for ALS. Experimental paradigms used we... |
Copper(2+) (2E,2'E)-2,2'-[(2E,3E)-2,3-butanediylidene]bis(N-methylhydrazinecarbimidothioate) |
Hydrazinecarbothioamide, 2,2'-[(1E,2E)-1,2-dimethyl-1,2-ethanediylidene]bis[N-methyl-, copper(2+) salt, (2E,2'E)- (1:1) |
ATSM CU-64 |
0YDK1H9L3A |
Cu-ASTM |